NSCLC Therapeutics Market Opportunities Discussed in New FirstWord Research Report Published at MarketPublishers.com31 Mar 2014 • by Natalie Aster
LONDON – Considerable changes are likely to affect the non-small cell lung cancer (NSCLC) treatment algorithm – and they are coming soon. Revolutionary novel NSCLC immunotherapies, novel personalised treatment options and further NSCLC drug developments are all primed to roll out in the short run. Nice opportunities exist in inventing a novel therapy to deal with the T790 mutation that is responsible for close to 50% of acquired resistance cases.
From cancer vaccines to checkpoints inhibitors, a number of therapies currently in late-stage development are to be launched in the offing. Programmed cell death protein 1 (PD-1) pathway inhibitors offer the most promising opportunities. The intensive race is on between Roche’s RG7446, Merck & Co.’s MK-3475 and Bristol-Myers Squibb’s nivolumab to turn out to be the first to be approved. Personalised targeted therapy has been a paradigm shift towards evaluating patients’ treatment options based on mutation status. Xalkori (Crizotinib, Pfizer) takes the lead in this respect; nevertheless, it has to face pending competition from some other therapies which are presently in various development stages.
New research report “Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insight” created by FirstWord provides an all-round assessment of the NSCLC therapeutics market with a particular focus on its future growth prospects.
The comprehensive report offers the unique KOL analysis of NSCLC therapeutics market, sheds light on the most recent and significant developments within the NSCLC treatment field, besides delving into the competitive environment. The topical study presents in-depth insights into the present and future treatment landscapes, contains detailed interviews with 12 experienced and highly-recognised KOLs across North America and Europe, and scrutinises the NSCLC treatment guideline development. Besides, the research report identifies and thoroughly discusses the major factors and events expected to shape the NSCLC treatment market.
Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insight
Published: March, 2014
Price: US$ 4,995.00
Other New Reports by FirstWord Include:
- Multiple Sclerosis - KOL Insight and Consensus Outlook Modules
- Physician Views: Can Bayer deliver on its Xarelto bullishness?
- The Reality of Market Access in Europe: the role of Health Technology Assessment
- Physician Views: What role will device development play in the future GLP-1 agonist market?
More new market research reports by the publisher can be found at FirstWord page.